Effects of cyclooxygenases inhibitors on vasoactive prostanoids and thrombin generation at the site of microvascular injury in healthy men

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 23, Issue 6, 2003, Pages 1111-1115

  Tuleja, Ewa ^a   Mejza, Filip ^a   Cmiel, Adam ^b   Szczeklik, Andrzej ^a,b  

^a AGH UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Poland)

^b JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

Author keywords

Cyclooxygenase inhibitors; Myocardial infarction; Prostaglandins; Risk factors; Thrombin

Indexed keywords

ACETYLSALICYLIC ACID; DICLOFENAC; NAPROXEN; PROSTACYCLIN; PROSTAGLANDIN SYNTHASE INHIBITOR; PROSTANOID; ROFECOXIB; THROMBIN; THROMBOXANE;

ADULT; ARTICLE; BLEEDING TIME; BLOOD VESSEL INJURY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG MECHANISM; DRUG POTENCY; DRUG SAFETY; FATTY ACID SYNTHESIS; HEMOSTASIS; HUMAN; MALE; MICROVASCULATURE; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THROMBIN TIME;

6-KETOPROSTAGLANDIN F1 ALPHA; ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; BLEEDING TIME; BLOOD PLATELETS; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; DICLOFENAC; DOUBLE-BLIND METHOD; ENDOTHELIUM, VASCULAR; FIBRINOLYTIC AGENTS; HUMANS; ISOENZYMES; LACTONES; MALE; MEMBRANE PROTEINS; NAPROXEN; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; SULFONES; THROMBIN; THROMBOXANE B2;

EID: 0038797759     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.0000074879.19006.51     Document Type: Article

References (37)

1. FitzGerald GA, Patrono C. The coxibs, selective inhibitors of cyclooxygenase-2. N Engl J Med. 2001;345:433-441.
2. Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, Day R, Ferraz Mb, Hawkey CJ, Hochberg MC, Kvien TK, Schnitzer TJ. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis: VIGOR Study Group. N Engl J Med. 2000;343:1520-1528.
3. Warner TD, Giuliano F, Vojnovic I, Bukasa A, Mitchell JA, Vane JR. Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclooxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. Proc Natl Acad Sci U S A. 1999;96:7563-7568.
4. McAdam BF, Catella-Lawson F, Mardini IA, Kapoor S, Lawson JA, FitzGerald GA. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. Proc Natl Acad Sci U S A. 1999;96:272-277.
5. Mukherjee D, Nissen SE, Topol EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA. 2001;286:954-959.
6. Konstam MA, Weir MR, Reicin A, Shapiro D, Sperling RS, Barr E, Gertz BJ. Cardiovascular thrombotic events in controlled clinical trials of rofecoxib. Circulation. 2001;104:2280-2288.
7. Vane RJ. Back to an aspirin a day? Science. 2002;296:474-475.
8. Szczeklik A, Krzanowski M, Gora P, Radwan J. Antiplatelet drugs and generation of thrombin in clotting blood. Blood. 1992;80:2006-2011.
9. Undas A, Brummel K, Musiał J, Mann KG, Szczeklik A. Blood coagulation at the site of microvascular injury: effects of low-dose aspirin. Blood. 2001;96:2423-2431.
10. 2 generation by low-dose aspirin at the site of plug formation in man in vivo. Circulation. 1987;75:1025-1029.
11. 1α in humans in response to a standardized vascular injury and the influence of aspirin. Circulation. 1989;79:29-38.
12. Thorngren M, Vinge E. Thromboxane A2 and prostacyclin release in bleeding time blood during primary haemostasis in healthy individuals. Acta Med Scand. 1988;223:187-190.
13. Kallmann R, Nieuwenhuis HK, de Groot PG, van Gijn J, Sixma JJ. Effects of low doses of aspirin, 10 mg and 30 mg daily, on bleeding time, thromboxane production and 6-keto-PGF1 alpha excretion in healthy subjects. Thromb Res. 1987;45:355-361.
14. Szczeklik A, Musiał J, Undas A. Reasons for resistance to aspirin in cardiovascular disease. Circulation. 2002;106:181e.
15. Nowak J, FitzGerald GA. Redirection of prostaglandin endoperoxide metabolism at the platelet-vascular interface in man. J Clin Invest. 1989;83:380-385.
16. Caughey GE, Cleland LG, Penglis PS, Gamble JR, James MJ. Roles of cyclooxygenase (COX)-1 and COX-2 in prostanoid production by human endothelial cells: selective up-regulation of prostacyclin synthesis by COX-2. J Immunol. 2001;167:2831-2838.
17. Hennan JK, Huang J, Barrett TD, Driscoll EM, Willens DE, Park AM, Crofford LJ, Lucchesi BR. Effects of selective cyclooxygenase-2 inhibition on vascular responses and thrombosis in canine coronary arteries. Circulation. 2001;104:820-825.
18. Szczeklik A, Musiał J, Undas A. Inhibition of thrombin generation by simvastatin and lack of additive effects of aspirin in patients with marked hypercholesterolemia. J Am Coll Cardiol. 1999;33:1286-1293.
19. 2. Science. 2002;296:539-541.
20. Ray WA, Stein CM, Hall K, Daugherty JR, Griffin MR. Non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease: an observational cohort study. Lancet. 2002;359:118-123.
21. Linton MF, Fazio S. Cyclooxygenase-2 and atherosclerosis. Curr Opin Lipidol. 2002;13:497-504.
22. Wong E, Huang JO, Tagari P, Riendeau D. Effects of COX-2 inhibitors on aortic prostacyclin production in cholesterol-fed rabbits. Atherosclerosis. 2001;157:393-402.
23. Belton O, Byrne D, Kearney D, Leahy A, FitzGerald DJ. Cyclooxygenase-1 and -2-dependent prostacyclin formation in patients with atherosclerosis. Circulation. 2000;102:840-845.
24. Pitt B, Pepine C, Willerson JT. Cyclooxygenase-2 inhibition and cardiovascular events. Circulation. 2002;106:167-169.
25. Chenevard R, Hürlimann D, Béchir M, Enseleit F, Spieker L, Hermann M, Riesen W, Gay S, Gay RE, Neidhart M, Michel B, Luscher TF, Noll G, Ruschitzka F. Selective COX-2 inhibition improves endothelial function in coronary artery disease. Circulation. 2003;107:r15-r19.
26. Halushka MK, Halushka PV. Why are some individuals resistant to the cardioprotective effects of aspirin? Could it be thromboxane A2? Circulation. 2002;105:1620-1622.
27. Cipollone F, Prontera C, Pini B, Marini M, Fazia M, De Cesare D, Iezzi A, Ucchino S, Boccoli G, Saba V, Chiarelli F, Cuccurullo F, Mezzetti A. Overexpression of functionally coupled cyclooxygenase-2 and prostaglandin E synthase in symptomatic atherosclerotic plaques as a basis of prostaglandin E(2)-dependent plaque instability. Circulation. 2001;104:921-927.
28. Mebaaza A, DeKeulenaer GW, Paqueron X, Andries LJ, Ratajczak P, Lanone S, Frelin C, Longrois D, Payen D, Brutsaert DL, Sys SU. Activation of cardiac endothelium as a compensatory component in endotoxin-induced cardiomyopathy. Circulation. 2001;104:3137-3144.
29. Altman R, Luciardi HL, Muntaner J, Del Rio F, Berman SG, Lopez R, Gonzalez C. Efficacy assessment of meloxicam, a preferential cyclooxygenase-2 inhibitor, in acute coronary syndromes without ST-segment elevation. Circulation. 2002;106:191-195.
30. Burleigh ME, Babaev VR, Oates JA, Harris RC, Gautam S, Riendeau D, Marnett LJ, Morrow JD, Fazio S. Linton MRF. Cyclooxygenase-2 promotes early atherosclerotic lesion formation in LDL receptor-deficient mice. Circulation. 2002;105:1816-1823.
31. FitzGerald GA, Oates JA, Hawiger J, Maas RL, L Jackson Roberts II, Lawson JA, Brash AR. Endogenous biosynthesis of prostacyclin and thromboxane and platelet function during chronic administration of aspirin in man. J Clin Invest. 1983;71:676-688.
32. Van Hecken A, Schwartz JI, Depre M, De Lepeleire I, Dallob A, Tanaka W, Wynants K, Buntinx A, Arnout J, Wong PH, Ebel DL, Gertz BJ, De Schepper PJ. Comparative inhibitory activity of rofecoxib, meloxicam, diclofenac, ibuprofen and naproxen on COX-2 versus COX-1 in healthy volunteers. J Clin Pharmacol. 2000;40:1109-1120.
33. Cattela-Lawson F, Reilly MP, Kapoor SC, Cucchiara AJ, DeMarco S, Tournier B, Vyas SN, FitzGerald GA. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med. 2001;345:1809-1817.
34. Solomon DH, Glynn RJ, Levin R, Avorn J. Nonsteroidal anti-inflammatory drug use and acute myocardial infarction. Arch Intern Med. 2002;162:1099-1104.
35. Rahme E, Pilote L, LeLorier J. Association between naproxen use and protection against acute myocardial infarction. Arch Intern Med. 2002;162:1111-1115.
36. Watson DJ, Rhodes T, Cai B, Guess HA. Lower risk of thromboembolic cardiovascular events with naproxen among patients with rheumatoid arthritis. Arch Intern Med. 2002;162:1105-1110.
37. Verma S, Raj SR, Shewchuk L, Mather KJ, Anderson TJ. Cyclooxygenase-2 blockade does not impair endothelial vasodilator function in healthy volunteers: randomized evaluation of rofecoxib versus naproxen on endothelium-dependent vasodilation. Circulation. 2001;104:2879-2882.